News from sosei group corporation A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

( Bloomberg:ALEMK@BB,RICS:ALEMK,ISIN:BE0003843605)

Jul 27, 2013, 10:41 ET

First in Class Once-Daily Dual Bronchodilator Ultibro® Breezhaler® (QVA149) Gains Positive CHMP Opinion for the Treatment of COPD

- QVA149 (indacaterol/glycopyrronium) is the first once-daily fixed-dose combination of both a LABA and a LAMA bronchodilator to gain...

Mar 12, 2013, 02:30 ET

Sosei Announces Initiation of Phase III Study for SO-1105 for the Treatment of Oropharyngeal Candidiasis

Sosei Group Corporation (TSE Mothers Index: 4565), the biopharmaceutical company, today announces that its Japanese subsidiary, Sosei Co., Ltd.,...

Nov 07, 2012, 01:45 ET

Sosei Group Corporation: QVA149 Filed by Licensing Partner as a Once-Daily Maintenance Treatment for COPD in Japan

Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565) confirms the information released today by Novartis Pharma K.K. that it has submitted...

Oct 25, 2012, 01:33 ET

Sosei Group Corporation: QVA149 Filed as a Once-Daily Maintenance Treatment for COPD in Europe

Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565) confirms the information released today by Novartis that QVA149, (indacaterol maleate /...

Oct 01, 2012, 02:07 ET

Seebri® Breezhaler® Receives European Commission Approval as Once-Daily Maintenance Treatment for COPD in the EU

- Approval triggers $10m milestone payment to Sosei - Seebri®  Breezhaler®  44 mcg delivered dose...

Sep 28, 2012, 01:26 ET

Seebri® Inhalation Capsules Receive MHLW Approval as Once-daily Maintenance Treatment for COPD in Japan

- Marks first approval for glycopyrronium bromide in COPD, with approval also expected in the EU in 2012 - Approval triggers...

Sep 03, 2012, 02:40 ET

Sosei Group Corporation: Data at ERS Shows Efficacy of Once-daily COPD Portfolio Versus Comparators, Further Establishes Dual-bronchodilator QVA149

- QVA149 demonstrated superior bronchodilation compared to indacaterol 150 mcg, glycopyrronium 50 mcg, salmeterol/fluticasone 50/500...

Aug 30, 2012, 02:11 ET

Sosei Group Corporation QVA149 Phase III Study Meets Primary Endpoint in Reducing Exacerbations in COPD Patients and Filings in EU and Japan by End of Year

- SPARK demonstrated QVA149 statistically significantly reduced rate of moderate-to-severe exacerbations compared to glycopyrronium 50...

Jul 02, 2012, 03:14 ET

Sosei Announces Successful Completion of Phase I Study for SO-1105 for the Treatment of Oropharyngeal Candidiasis

Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565), the biopharmaceutical company, today announces that its wholly owned Japanese...

Jun 24, 2012, 19:01 ET

Once-daily Seebri® Breezhaler® Receives Positive CHMP Opinion to Treat COPD Patients in the EU

- COPD patients in Phase III GLOW trials experienced improved lung function, reduced shortness of breath, reduced exacerbations, and improved...

Jun 22, 2012, 14:37 ET

Once-daily Seebri® Breezhaler® Receives Positive CHMP Opinion to Treat COPD Patients in the EU

- COPD patients in Phase III GLOW trials experienced improved lung function, reduced shortness of breath, reduced exacerbations, and improved...

May 17, 2012, 01:30 ET

NVA237 Phase III GLOW2 Data at American Thoracic Society (ATS) International Conference and Phase II Clinical Trial Update

- GLOW2 study showed NVA237 superior to placebo and similar to OL tiotropium in increasing lung function, improving COPD symptoms and...

Apr 24, 2012, 01:20 ET

QVA149 ILLUMINATE Phase III COPD Study Meets Primary Endpoint and Clarification of Anticipated Timing of US Filings for NVA237 and QVA149

- Superior lung function with once-daily QVA149 compared with twice-daily Seretide[®1] - Study is part of...

Apr 02, 2012, 01:30 ET

QVA149 Phase III COPD Studies Met Primary Endpoints

Efficacy, safety and exercise endurance primary endpoints all met Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565), confirms the...

Mar 08, 2012, 01:30 ET

Sosei Announces Initiation of Phase I Study for SO-1105

Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565), the biopharmaceutical company, today announces that its wholly owned Japanese...

Mar 08, 2012, 01:30 ET

Sosei Announces Private Placement of New Shares by its Subsidiary

Sosei Group Corporation ("Sosei". TSE Mothers Index: 4565), announces that the board of its fully-owned subsidiary, Sosei Co., Ltd resolved to...

Sep 27, 2011, 01:15 ET

NVA237 Filed in Europe and Positive Phase III Data at European Respiratory Society Congress

NVA237 has been filed for marketing authorisation by Novartis with the European Medicines Agency (EMA) under the brand-name Seebri®...

Aug 22, 2011, 04:00 ET

Sosei to Receive Grant from NEDO's FY2011 Innovation Promotion Programme for Development of Innovative Ophthalmic Solutions

? Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565), announces that its wholly owned subsidiary Activus Pharma Co., Ltd. ("Activus") is...

Jun 30, 2011, 02:00 ET

Phase III Study Shows Once-Daily NVA237 is Superior to Placebo and Similar to Tiotropium in Improving Lung Function in COPD

- GLOW2 Study Shows NVA237 Provides Superior24-hour Bronchodilation to Placebo (p<0.001) with Comparable Efficacy to Open-Label...

May 23, 2011, 02:00 ET

Sosei to Launch NorLevo(R) TABLETS 0.75mg (Emergency Contraceptive Pill) in Japan

Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565), the biopharmaceutical company, today announced that Sosei Co., Ltd., its wholly owned...